FOCUSED ON WOMEN'S HEALTH and hormone-sensitive cancer for healthy aging worldwide

Discover our research

Our solution

A low dose (6.5 mg) of intravaginal DHEA permits a local action while maintaining serum estrogens or androgens as well as their metabolites within normal values.

Find out about Intrarosa™

Our goal as a Quebec company

 

Our main goal is to offer all women in the world, in addition to the treatment of vaginal atrophy, the benefits of effective, physiological and non-negative treatments for all menopausal problems, including hot flashes, bone loss and muscle loss.

Research and Development

Latest News

Read the news

Theramex Australia Enters Partnership With Endoceutics For Intrarosa® For The Treatment Of Postmenopausal Vulvovaginal Atrophy

February 14, 2022

Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has expanded its original agreement with Endoceutics to commercialise Intrarosa® (prasterone) in Australia.

Lupin Pharma Canada Announces Partnership with Endoceutics for the Commercialization of INTRAROSA®

March 8, 2021

Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, today announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize INTRAROSA® in Canada.

ENDOCEUTICS ANNOUNCES ACQUISITION OF THE INTRAROSA® U.S. COMMERCIAL RIGHTS BY MILLICENT PHARMA

May 27, 2020

Quebec City, Canada; Endoceutics announces that the U.S. commercial rights for its flagship product, INTRAROSA®, were transferred to Millicent Pharma following a divestiture process announced in January 2020 by AMAG Pharmaceuticals.